

Phospho-PI3 Kinase p85 (Tyr458)/p55 (Tyr199) (1A11) rabbit mAb APC conjugate

www.abwizbio.com
Support: info@abwizbio.com
Order: sales@abwizbio.com


Catalog: #2069

Store at: 2-8°C

For Research Use Only. Not For Use In Diagnostic Procedures.

Applications	Detection	Clonality	Isotype
Flow Cytometry	N/A	Monoclonal	Rabbit IgGk

Format:	APC
Cross Reactivity:	Predicted to work with mouse, rat, and other homologues.
Formulation:	1X PBS, 0.09% NaN ₃ , 0.2% BSA
Preparation:	Protein A+G
Reactivity:	Human,Mouse
Recommended Usage:	For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells or 5 µL per 100 µL of staining volume. It is recommended that the reagent be titrated for optimal performance for each application.
Immunogen:	A synthetic phospho-peptide corresponding to residues surrounding Tyr458 of human phospho PI3K p85
Description:	Phosphoinositidine 3-kinase (PI3K) targets phosphoinositide lipids for phosphorylation at the D-3 position to serve as a second messenger molecule to activate signaling pathways in response to extracellular stimuli. Akt/protein kinase B (PKB) is a major downstream target of PI3K. The multiple forms of PI3K have different specificities and different affinities for various phosphatidylinositol forms. The PH domains of downstream proteins in these pathways bind to these secondary messengers, causing altered cellular distribution and subsequent kinase activation. The PI3K/Akt pathway is altered in a large proportion of human cancers, as this pathway regulates cellular survival, cell cycle progression, and cell growth.
References:	Franke TF, Kaplan DR, and Cantley LC. (1997) Cell. 88: 435-437. Fresno JAV, Casado E, Cejas P, et al. (2004) Cancer Treatment Reviews. 30: 193-204.



Flow cytometric analysis of Ramos cells untreated and unstained as negative control (blue) or untreated (red) or treated with pervanadate (green) and stained using Phospho-PI3 Kinase p85 (Tyr458)/p55 (Tyr199) antibody PI3KY458-1A11 APC conjugate. Cat. #2069.